AI Metrics wins FDA nod for liver biopsy software

By staff writers

November 17, 2020 -- Artificial intelligence (AI) software developer AI Metrics has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for its Liver Surface Nodularity (LSN) virtual liver biopsy software.

Designed to assist physicians in staging chronic liver disease, LSN's algorithms assess nodules along the liver's surface on CT images, according to the vendor. The software module will be distributed by AI Metrics partner Imaging Biometrics.

The FDA clearance is the first for AI Metrics.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking